Scade Medical Ltd.

www.scade-medical.com (under construction)

Formerly DOSI - Medical Imaging Systems Ltd.

High-Tech Company

Ceased to Operate Q4/2024

TECH VERTICALS

Artificial Intelligence, Computer Vision, Healthtech, Life Sciences, Machine Vision, Medical Devices, MedTech

General Data

Sector	Medical Devices
Company Stage:	R&D
Established	2013
Number of Employees	3
Reg. Number:	abCDe

DESCRIPTION

Scade Medical (formerly DOSI - Medical Imaging Systems) is developing a non-invasive imaging device designed to detect and follow up sub-dermal distortions in moles before deterioration to cancer. Often these changes indicate the development of a cancerous process which requires urgent intervention of certified dermatologist. Scade's concept is to enable Dermatologists or GP’s householders to scan underneath lesions and save it in a database for follow up. Scade has developed a patented robust image acquisition and processing algorithm that is implemented within a unique scanner to create a state-of-the-art diagnostic tool for skin cancer. The device detects and enhances minor deformations within the dermis and epidermis. The device is intended to support and assist dermatologists in diagnosing skin cancer at its early stages, in particular malignant melanoma (MM).

TECHNOLOGY

The company's technology is based on differential optical spectro-polarimetric imaging. The image is acquired under well-defined parameters and conditions, thus enabling subsequent processing and presentation of the degree of deformation within the examined tissue. This level of distortion is otherwise inaccessible to dermatologists. The device makes use of the spectral part solely to enable deformation calculation in different skin layers. It does not look for the spectral signature of the suspected lesion. Therefore, lesions that do not exhibit odd or suspected pigmentation can also be detected by the technology. This constitutes a prominent advantage over existing technologies and opens new possibilities for lesion nature detection and nevi type classification. The technology also facilitates accurate detection of lesion margins, thus avoiding unnecessary repeated excision procedures, scarring and skin implants.

Scade initially focuses on the clinical indication for the early detection of malignant melanoma. Treatment effectiveness and survival rate for this life-threatening disease depend on early detection. The market for skin lesion inspection is huge and is marked by a high procedure volume. At a second stage, Scade will address a second clinical indication of margin identification during lesion excision. At a third stage, Scade will expand its first clinical indication to encompass non-melanoma skin cancers (BCC and SCC). Finally, Scade will launch the first regulatory approved home diagnostic device, which will promote self-examination and early treatment of skin cancer.

Products and Phases

Product	Phase
DOSI Scanner	Phase I
Revolutionary patent protected scanner for spotting and follow up of skin distortions underneath moles that might deteriorate to cancer.

	TARGET MARKETS
	Dermatologists, Plastic Surgeons, Home Users

	BUSINESS MODEL
	B2C

COMPETITORS

STRATA Skin Sciences (Melafind) , Vivascope , 3Gen (DermLite) , MedX Health (MoleMate)

CONTACT INFO

Expand / Collapse All

Main Address: Shoham, Israel

Address	19 Sapir St.
City	Shoham
Country	Israel
Zip	6085000

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Gabi Mizrachi	Co-Founder	Paymaxs (VP, Business Development)
Dr. Ofir Aharon	Co-Founder	Scade Medical (CEO & CTO)

Last Updated:	abCDe
IVC Number:	abCDe